OXB to Present at Rodman & Renshaw Conference

RNS Number : 7854P

Oxford Biomedica PLC

05 September 2017

 

Oxford BioMedica to Present at Rodman & Renshaw Annual Global Investment Conference, New York

Oxford, UK - 5 September 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference in New York on Tuesday 12 September at 08:20 EST.  

-Ends-

For further information, please contact:

Oxford BioMedica plc:    Tel: [phone]

John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer

Financial PR Enquiries:  Tel: [phone]

Mary-Jane Elliott / Matthew Neal / Philippa Gardner / Laura Thornton
Consilium Strategic Communications

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.  Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

NRAQZLFBDKFFBBK